Open AccessCost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain
Author(s) -
Margarita Majem,
Rosa Álvarez,
Ana Laura Ortega,
Lucía Ruiz de Alda,
Rocío Gordo,
José-Francisco García,
Yoana Ivanova-Markova,
Almudena González-Domínguez,
Raquel Sánchez San Cristóbal,
Federico Rojo
Publication year - 2022
Publication title -
global and regional health technology assessment
Language(s) - English
Resource type - Journals
eISSN - 2283-5733
pISSN - 2284-2403
DOI - 10.33393/grhta.2022.2449
Subject(s) - alectinib , anaplastic lymphoma kinase , medicine , lung cancer , oncology , alk inhibitor , crizotinib , malignant pleural effusion
In recent years, target therapies to specific molecular alterations in advanced non-small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheless, ALK diagnosis is not performed in all NSCLC patients in Spain. The objective of this study is to estimate in monetary terms the benefit for the Spanish society of ALK diagnosis in advanced NSCLC patients.